At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 78 enrolled
Drug / intervention
LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Calcipotriol Plus Betamethasone Dipropionate Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
In Brief
A Phase 2 clinical trial evaluating LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension) for Scalp Psoriasis. Completed, enrolled 78 participants across 17 sites in 3 countries.
Detailed Summary
The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 gel in adolescent subjects (aged 12 to 17) with scalp psoriasis. LEO 80185 gel has marketing approval in many countries under the brand names Xamiol® gel and Taclonex Scalp® Topical Suspension for the treatment of scalp psoriasis in adults. No studies have been performed in subjects younger than 18 years
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScalp Psoriasis
CountriesCanada, France, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2010
First PostedMay 2010
Primary CompletionAug 2012
Study CompletionOct 2012
TodayJul 2026
First PostedMay 10, 2010
Enrollment StartMay 1, 2010
Primary CompletionAug 1, 2012
Study CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.1 years ago
Interventions
LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)drug
Once daily application